Reciprocal regulation of 5alpha-dihydrotestosterone, interleukin-6 and interleukin-8 during proliferation of epithelial ovarian carcinoma.

Department of Immunology, Tianjin Medical University, Tianjin, PR, China.
Cancer biology & therapy (Impact Factor: 3.29). 07/2007; 6(6):864-71.
Source: PubMed

ABSTRACT Androgens have been associated with the risk for epithelial ovarian cancer (OVCA). Both IL-6 and IL-8 are also likely involved in the progression of OVCA. In order to discover the underline molecular mechanism, we investigated the modulation of androgen and two cytokines in the growth of epithelial OVCA. In these studies, the effect of 5alpha-dihydrotestosterone (DHT) on the expression levels of IL-6 and IL-8 was investigated. The effect of IL-6 and IL-8 on cell growth and androgen receptor (AR) expression was also analyzed. Gene expression profile analysis revealed that SKOV-3 cells, which express AR, IL-6 and IL-8 receptors, are suitable model for this study. We found that IL-6 and IL-8 markedly promoted SKOV-3 cell proliferation. Furthermore, DHT enhanced IL-6 and IL-8 secretion. Flutamide (Flu), an AR antagonist, completely abolished DHT-stimulated cell growth and the expression of IL-6 and IL-8. IL-6- or IL-8-induced cell proliferation was completely blocked by their specific neutralizing antibodies, which partially inhibited DHT-induced cell growth. In the absence of androgen, both cytokines enhanced AR expression and AR promoter activation, which was completely blocked by Flu. However, Flu failed tor educe IL-6-/IL-8-induced cell growth. Pretreatment of SKOV-3 cells with p38 MAPK, MEK1/2, and ErbB2 MAPK inhibitors, respectively, blocked IL-6-mediated enhancement of AR transcription while Src inhibitor blocked IL-8 induced AR transcription. These results provide a novel mechanism that androgens, IL-6 and IL-8 may form a common amplifying signaling cascade to modulate OVCA growth. Androgen-induced OVCA proliferation is partially occurring via enhanced IL-6 and IL-8 expression, and IL-6/IL-8 could also promote OVCA growth by activation of AR gene promoter.

  • [Show abstract] [Hide abstract]
    ABSTRACT: It has been shown that IL-8 is elevated in ovarian cyst fluid, ascites, serum, and tumor tissue from ovarian cancer (OVCA) patients, and increased IL-8 expression correlates with poor prognosis and survival. However, the exact role that IL-8 plays in this malignancy or whether IL-8 can regulate malignant behavior has not been established. Here we demonstrate that overexpression of IL-8 in non-IL-8-expressing A2780 cells (by transfecting with plasmid encoding for sense IL-8) increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion while depletion of endogenous IL-8 expression in IL-8-overexpressing SKOV-3 cells (by transfecting with plasmid encoding for antisense IL-8) decreases the above effects. Further investigation indicates that IL-8-stimulated cell proliferation correlates with alteration of cell cycle distribution by increasing levels of cell cycle-regulated Cyclin D1 and Cyclin B1 proteins as well as activation of PI3K/Akt and Raf/MEK/ERK, whereas IL-8-enhanced OVCA cell invasive correlates with increased MMP-2 and MMP-9 activity and expression. Our data suggest that IL-8 secreted by OVCA cells promotes malignant behavior of these cells via inducing intracellular molecular signaling. Therefore, modulation of IL-8 expression or its related signaling pathway may be a promising strategy for controlling the progression and metastasis of OVCA.
    Cytokine 05/2012; 59(1):145-55. DOI:10.1016/j.cyto.2012.04.013 · 2.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The androgen receptor (AR) is expressed in a majority of ovarian carcinomas, but its role in disease development remains unclear. In this study, AR and a novel AR molecular chaperone called small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA) were investigated to assess their potential role in ovarian carcinogenesis. First, an AR and SGTA-positive ovarian cancer cell line was identified to examine whether SGTA influenced AR subcellular localization. Next, relative protein levels of AR and SGTA were measured in two sets of clinical samples: (1) 46 serous ovarian carcinomas (stages I-IV), 9 serous borderline tumors, and 11 benign ovarian tumors; and (2) 24 patient-matched stage III primary and metastatic serous ovarian tumors. Ablation of SGTA protein in OVCAR3 cells significantly increased AR nuclear localization under basal (p ≤ 0.001) and androgen-stimulated (p ≤ 0.001) conditions. In the first clinical set, AR levels were significantly lower in early- (I/II) and late-stage (III/IV) cancers compared with benign (p ≤ 0.001) but not borderline ovarian tumors. SGTA alone did not discriminate between groups but the AR/SGTA ratio was significantly lower in carcinomas and borderline tumors compared with benign tumors (p ≤ 0.001 and 0.015, respectively). In the second clinical set, matched primary and metastatic serous ovarian cancers did not significantly differ for any parameter measured. Collectively, our results suggest that SGTA can influence AR signaling in ovarian cancer cells and that AR signaling capacity may be reduced with the development but not metastatic progression of serous ovarian cancer.
    Hormones and Cancer 02/2013; 4(3). DOI:10.1007/s12672-013-0135-0
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Experiments conducted in the microgravity environment of space are not typically at the forefront of the mind of a cancer biologist. However, space provides physical conditions that are not achievable on Earth, as well as conditions that can be exploited to study mechanisms and pathways that control cell growth and function. Over the past four decades, studies have shown how exposure to microgravity alters biological processes that may be relevant to cancer. In this Review, we explore the influence of microgravity on cell biology, focusing on tumour cells grown in space together with work carried out using models in ground-based investigations.
    Nature Reviews Cancer 04/2013; DOI:10.1038/nrc3507 · 29.54 Impact Factor


Available from